Evaluation of Bevacizumab and Weekly Docetaxel in Elderly (greater than or equal to 75 Years) Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Aug 2012 Planned End Date changed from 1 Feb 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov (NCT01665443).